Background {#s1}
==========

Approximately 238,719 new patients with ovarian cancer are diagnosed each year worldwide. Although the survival trends between 1995--1999 and 2010--2014 were relatively constant in most countries, 5-year survival was still \<50% for women diagnosed in 2010--2014 ([@B1]). Approximately 22,240 newly diagnosed ovarian cancer and 14,070 ovarian cancer-related deaths are expected in the United States (US) in 2018 ([@B2]). Epithelial ovarian cancer (EOC) is the most common histological subtype of ovarian cancer, and 90% of patients are diagnosed with EOC. However, 80% of patients have been diagnosed with advanced stage disease ([@B2]) due to lack of specificity and obvious symptoms ([@B3], [@B4]). In addition, there are still lack of sensitive and specific screening techniques and biomarkers for ovarian cancer ([@B3]--[@B6]).

A previous Surveillance, Epidemiology and End Results (SEER) study including EOC patients between 1973 and 1997, the 5-year relative survival was gradually increased in patients with localized (84% in 1973--1979 to 92% in 1990--1997), regional (49% in 1973--1979 to 77% in 1990--1997) and distant (17% in 1973--1979 to 27% in 1990--1997) stage ([@B7]). The significantly increased the survival in regional stage may be due to the use of paclitaxel-containing chemotherapy in clinical practice. In a recent ovarian cancer statistics between 2007 to 2013 from US, the 5-year survival rate was 89 and 71% in stage I and II EOC patients, respectively, while it has significantly decreased to 41 and 20% in those with stage III and IV disease, respectively ([@B2]). Although the above three studies have different definitions of staging system, the ovarian cancer mortality was slowly decreasing in recent decades, which may be related to its unknown etiology, lack of effective diagnostic methods in the early disease process, and lack of effective treatment.

Advances in surgical and chemotherapeutic approaches have improved management of EOC in recent decades. The cytoreductive surgery (debulking) and paclitaxel-containing chemotherapy were introduced into the clinical practice of EOC in the late 1960s and early 1990s, respectively. In the current clinical practice, the standard treatment for early-stage EOC is complete surgical staging procedure including examination of the abdominal cavity, omentectomy, several prescribed biopsies, and thorough pelvic and para-aortic lymph node sampling. Debulking surgery in combination with neoadjuvant or adjuvant platinum/taxane-based chemotherapy has become the standard treatment for patients with advanced EOC ([@B8], [@B9]). The main goal of all these therapeutic changes is to improve the prognosis. However, the results of several population-based studies on survival trends over time in EOC are inconsistent ([@B10]--[@B15]), which may be due to the different period of diagnosis, heterogeneity of the population, and different treatment strategies. A SEER study included EOC patients between 1973 and 1997, reported a gradual increase in survival over time. However, the 5-year overall survival (OS) only increased slightly from 40% in 1980--1989 to 45% in 1990--1997 ([@B7]). In addition, another SEER study included Hispanic EOC patients during 1992--2013, and the results showed no significantly difference in survival outcomes among three periods of diagnosis 1992--1999, 2000--2006, and 2007--2013 ([@B16]). There are lacking studies regarding to the changes in the survival rates of EOC in the recent three decades over time. Due to improvements in diagnostic techniques, surgery, treatment, and individualized care, it is hypothesized that the survival rate of EOC may be further improved in recent decades. The purpose of the present study was to assess the survival trends of EOC between 1990 and 2014 using real-world data from SEER program.

Materials and Methods {#s2}
=====================

Patients
--------

Data on patients diagnosed with EOC from 1990 to 2014 were analyzed using the SEER 18 Regs Research Data of the National Cancer Institute ([@B17]). This cancer-registration database contains data on cancer incidence, demographic and clinicopathologic characteristics, first course of treatment, and survival of approximately 28% of the US population. Patients without a positive histology or with a prior malignancy diagnosis were excluded. The use of data from the SEER database was exempt from the approval process of the Institutional Review Board because its patient-related information is de-identified.

Measures
--------

Demographic, clinicopathologic, treatment variables, and vital status were included as follows: age, year of diagnosis, race/ethnicity, tumor grade, SEER stage, histological subtypes, surgery, chemotherapy, and marital status at diagnosis. Survival trends were examined over five time periods: 1990--1994, 1996--1999, 2000--2004, 2005--2009, and 2010--2014. Tumor grade was classified as well-differentiated, moderately differentiated, poorly differentiated, undifferentiated, or unknown tumor grade. The histologic subtypes were classified as serous, mucinous, endometrioid, and clear-cell. The SEER staging system corresponds to the commonly used International Federation of Gynecology and Obstetrics (FIGO) staging system, as follows: localized (I-A, I-B, I-not otherwise specified \[NOS\]), regional (FIGO I-C, II-A, II-B, II-C, II-NOS), distant (FIGO III-A, III-B, III-C, III-NOS, IV) ([@B18]).

Statistical Analysis
--------------------

The chi-square test and one-way analysis of variance were used to compare patients\' demographic, clinicopathologic, and treatment variables over the five periods. Kaplan--Meier analyses for 5-year cause-specific survival (CSS) and OS were performed using the log-rank test. CSS was defined as the time from the date of the initial diagnosis to the date of the ovarian cancer-related death. OS was defined as the time from the date of diagnosis to the date of death or last follow-up. The Cox proportional hazard was used for multivariate analyses. We included the following variables in the multivariate Cox proportional hazard models: age, race/ethnicity, grade, SEER stage, histological subtypes, surgery, chemotherapy, marital status, and years of diagnosis. Trends in survival were analyzed separately for localized, regional, and distant stages. All analyses were performed using SPSS version 22.0 (IBM Corporation, Armonk, USA), and *P* \< 0.05 was considered significant.

Results {#s3}
=======

Patient Characteristics
-----------------------

We identified 59,763 EOC patients in this study, including 6,586 (11.0%), 7,408 (12.4%), 15,348 (25.7%), 14,908 (24.9%), and 15,513 (26.0%) patients diagnosed in 1990--1994, 1995--1999, 2000--2004, 2005--2009, and 2010--2014, respectively ([Table 1](#T1){ref-type="table"}). Patients with poorly differentiated/undifferentiated disease increased from 43.1% in 1990--1994 to 56.1% in 2010--2014 (*P* \< 0.001). Patients with regional stage disease increased from 6.2% in 1990--1994 to 11.1% in 2010--2014 (*P* \< 0.001). Serous EOC was the most common histological subtype; the number of serous and clear-cell subtypes increased during the study period, whereas the number of endometrioid and mucinous subtypes decreased during the study period (*P* \< 0.001).

###### 

Baseline characteristics of patients between 1990 and 2014 by period of diagnosis.

  **Variables**                   ***N***     **1990--1994 (%)**   **1995--1999 (%)**   **2000--2004 (%)**   **2005--2009 (%)**   **2010--2014 (%)**   ***P***
  ------------------------------- ----------- -------------------- -------------------- -------------------- -------------------- -------------------- ---------
  **Age (years)**                                                                                                                                      
      Mean (years) (SD)           60 (13.8)   60.4 (14.6)          60.1 (14.1)          60.0 (13.9)          60.2 (13.7)          60.2 (13.4)          0.739
      \<20                        128         12 (0.2)             12 (0.2)             23 (0.1)             37 (0.2)             44 (0.3)             \<0.001
      20--39                      3,845       612 (9.3)            527 (7.1)            995 (6.5)            853 (5.7)            858 (5.5)            
      40--59                      24,831      2,330 (35.4)         3,018 (40.7)         6,563 (42.8)         6,424 (43.1)         6,496 (41.9)         
      60--79                      26,047      3,101 (47.1)         3,253 (43.9)         6,492 (42.3)         6,291 (42.2)         6,910 (44.5)         
     \>79                         4,912       531 (8.1)            598 (8.1)            1,275 (8.3)          1,303 (8.7)          1,205 (7.8)          
  **Race**                                                                                                                                             
      Non-hispanic white          45,028      5,386 (81.8)         5,737 (77.4)         11,947 (77.8)        11,074 (74.3)        10,884 (70.2)        \<0.001
      Non-hispanic black          3,701       352 (5.3)            416 (5.6)            916 (6.0)            929 (6.2)            1,088 (7.0)          
      Hispanic                    5,943       398 (6.0)            588 (7.9)            1,371 (8.9)          1,620 (10.9)         1,966 (12.7)         
      Other                       5,091       450 (6.8)            667 (9.0)            1,114 (7.3)          1,285 (8.6)          1,575 (10.2)         
  **Grade**                                                                                                                                            
      Well-differentiated         5,536       675 (10.2)           810 (10.9)           1,401 (9.1)          1,281 (8.6)          1,369 (8.8)          \<0.001
      Moderately differentiated   10,728      1,445 (21.9)         1,698 (22.9)         3,066 (20.0)         2,515 (16.9)         2,004 (12.9)         
      Poorly/undifferentiated     30,515      2,836 (43.1)         3,528 (47.6)         7,552 (49.2)         7,895 (53.0)         8,704 (56.1)         
      Unknown                     12,984      1,630 (24.7)         1,372 (18.5)         3,329 (21.7)         3,217 (21.6)         3,436 (22.1)         
  **SEER stage**                                                                                                                                       
      Localized                   13,165      1,531 (23.2)         1,691 (22.8)         3,194 (20.8)         3,273 (22.0)         3,476 (22.4)         \<0.001
      Regional                    5,289       408 (6.2)            517 (7.0)            1,255 (8.2)          1,394 (9.4)          1,715 (11.1)         
      Distant                     420,425     4,533 (68.8)         5,054 (68.2)         10,568 (68.9)        10,101 (67.8)        10,169 (65.6)        
      Unknown                     884         114 (1.7)            146 (2.0)            331 (2.2)            140 (0.9)            153 (1.0)            
  **Histological subtypes**                                                                                                                            
      Serous                      40,298      4,196 (63.7)         4,727 (63.8)         10,270 (66.9)        10,299 (69.1)        10,806 (69.7)        \<0.001
      Endometrioid                9,054       1,059 (16.1)         1,280 (17.3)         2,470 (16.1)         2,098 (14.1)         2,147 (13.8)         
      Mucinous                    5,815       927 (14.1)           881 (11.9)           1,490 (9.7)          1,287 (8.6)          1,230 (7.9)          
      Clear cell                  4,596       404 (6.1)            520 (7.0)            1,118 (7.3)          1,224 (8.2)          1,330 (8.6)          
  **Surgery**                                                                                                                                          
      No                          3,993       420 (6.4)            423 (5.7)            939 (6.1)            985 (6.6)            1,226 (7.9)          \<0.001
      Yes                         55,605      6,155 (93.5)         6,978 (94.2)         14,363 (93.6)        13,875 (93.1)        14,234 (91.8)        
      Unknown                     165         11 (0.1)             7 (0.1)              46 (0.3)             48 (0.3)             53 (0.3)             
  **Chemotherapy**                                                                                                                                     
      No/unknown                  17,926      2,150 (32.6)         2,279 (30.8)         5,139 (33.5)         4,474 (30.0)         3,884 (25.0)         \<0.001
      Yes                         41,837      4,436 (67.4)         5,129 (69.2)         10,209 (66.5)        10,434 (70.0)        11,629 (75.0)        
  **Marital status**                                                                                                                                   
      Unmarried                   25,697      2,927 (44.4)         3,168 (42.8)         6,456 (42.1)         6,451 (43.3)         6,695 (43.2)         \<0.001
      Married                     31,998      3,498 (53.1)         4,078 (55.0)         8,367 (54.5)         7,964 (53.4)         8,091 (52.2)         
      Unknown                     2,068       161 (2.4)            162 (2.2)            525 (3.4)            493 (3.3)            727 (4.7)            

*SD, standard deviation; SEER, surveillance, epidemiology and end results*.

Trends in Treatment
-------------------

The proportion of patients who received surgical treatment decreased from 93.5% in 1990--1994 to 91.8% in 2010--2014 (*P* \< 0.001). No significant difference was found over time in the proportion of patients in the localized (*P* = 0.140) and regional stages (*P* = 0.099) who received surgical treatment. However, the use of surgery decreased from 92.0% in 1990--1994 to 88.9% in 2010--2014 in the distant stage (*P* \< 0.001). The use of chemotherapy increased from 67.4% in 1990--1994 to 75.0% in 2010--2014. The use of chemotherapy in the localized stage increased from 34.0% in 1990--1994 to 49.7% in 2010--2014 (*P* \< 0.001). The use of chemotherapy in the regional stage increased from 70.6% in 1990--1994 to 78.5% in 2010--2014 (*P* \< 0.001), and it increased in the distant stage from 78.7% in 1990--1994 to 83.5% in 2010--2014 (*P* \< 0.001).

Survival Analysis
-----------------

The median follow-up was 40 months (range = 0--311 months). A total of 36,031 patients died, including 28,852 patients from ovarian cancer. The 5-year CSS and OS were 53.7 and 48.0%, respectively, and the median CSS and OS were 72.0 and 56.0 months, respectively.

The 5-year CSS rates were 48.6, 51.6, 52.2, 55.1, and 57.4% for patients diagnosed between 1990--1994, 1995--1999, 2000--2004, 2005--2009, and 2010--2014, respectively (*P* \< 0.001) ([Figure 1A](#F1){ref-type="fig"}), and the 5-year OS rates were 42.7, 46.4, 46.8, 49.3, and 51.7%, respectively (*P* \< 0.001) ([Figure 1B](#F1){ref-type="fig"}). [Figure 2](#F2){ref-type="fig"} lists the 5-year CSS ([Figure 2A](#F2){ref-type="fig"}) and OS ([Figure 2B](#F2){ref-type="fig"}) by year of diagnosis from 1990 to 2010. There was a 9.6% and a 10.9% absolute increase in the CSS and OS from 1990 to 2010, respectively.

![Trends in cause-specific survival **(A)** and overall survival **(B)** over time.](fonc-09-00639-g0001){#F1}

![The 5-year cause-specific survival **(A)** and overall survival **(B)** by each year of diagnosis from 1990 to 2010.](fonc-09-00639-g0002){#F2}

Multivariate Analysis of Prognostic Factors
-------------------------------------------

The results multivariate analysis showed that diagnoses in later years were associated with better CSS and OS ([Table 2](#T2){ref-type="table"}). Age, race/ethnicity, grade, SEER stage, histological subtypes, surgery, chemotherapy, and marital status were also the independent prognostic factors of CSS and OS.

###### 

Multivariate prognostic analyses of the entire cohort.

  **Variables**                   **CSS**   **OS**                                          
  ------------------------------- --------- -------------- --------- ------- -------------- ---------
  **Age (years)**                                                                           
      \<20                        1                                  1                      
      20--39                      0.993     0.677--1.456   0.970     1.156   0.805--1.662   0.432
      40--59                      1.418     0.971--2.070   0.071     1.895   1.323--2.713   \<0.001
      60--79                      1.893     1.296--2.763   0.001     2.865   2.001--4.102   \<0.001
     \>79                         3.076     2.104--4.497   \<0.001   5.060   3.530--7.251   \<0.001
  **Race**                                                                                  
      Non-hispanic white          1                                  1                      
      Non-hispanic black          1.191     1.136--1.248   \<0.001   1.256   1.205--1.309   \<0.001
      Hispanic                    0.940     0.901--0.981   0.004     0.990   0.953--1.027   0.584
      Other                       0.903     0.862--0.947   \<0.001   0.927   0.889--0.967   \<0.001
  **Grade**                                                                                 
      Well-differentiated         1                                  1                      
      Moderately differentiated   1.960     1.824--2.106   \<0.001   1.530   1.449--1.616   \<0.001
      Poorly/undifferentiated     2.350     2.194--2.518   \<0.001   1.814   1.722--1.911   \<0.001
      Unknown                     2.126     1.979--2.284   \<0.001   1.682   1.593--1.776   \<0.001
  **SEER stage**                                                                            
      Localized                   1                                  1                      
      Regional                    3.184     2.958--3.428   \<0.001   2.069   1.957--2.187   \<0.001
      Distant                     8.436     7.954--8.947   \<0.001   4.790   4.597--4.992   \<0.001
      Unknown                     4.272     3.826--4.772   \<0.001   2.417   2.205--2.648   \<0.001
  **Histological subtypes**                                                                 
      Serous                      1                                  1                      
      Endometrioid                0.656     0.627--0.686   \<0.001   0.744   0.717--0.772   \<0.001
      Mucinous                    1.130     1.072--1.192   \<0.001   1.240   1.188--1.295   \<0.001
      Clear cell                  1.093     1.036--1.153   0.001     1.012   0.965--1.062   0.617
  **Surgery**                                                                               
      No                          1                                  1                      
      Yes                         0.385     0.368--0.402   \<0.001   0.372   0.358--0.386   \<0.001
      Unknown                     0.546     0.429--0.694   \<0.001   0.612   0.501--0.749   \<0.001
  **Chemotherapy**                                                                          
      No/unknown                  1                                  1                      
      Yes                         0.873     0.848--0.898   \<0.001   0.800   0.780--0.820   \<0.001
  **Marital status**                                                                        
      Unmarried                   1                                  1                      
      Married                     0.873     0.852--0.894   \<0.001   0.845   0.827--0.864   \<0.001
      Unknown                     0.815     0.759--0.875   \<0.001   0.835   0.785--0.888   \<0.001
  **Year of diagnosis**                                                                     
      1990--1994                  1                                  1                      
      1995--1999                  0.921     0.882--0.962   \<0.001   0.923   0.889--0.959   \<0.001
      2000--2004                  0.864     0.832--0.898   \<0.001   0.877   0.848--0.907   \<0.001
      2005--2009                  0.772     0.742--0.803   \<0.001   0.801   0.773--0.830   \<0.001
      2010--2014                  0.671     0.642--0.702   \<0.001   0.699   0.672--0.727   \<0.001

*CSS, cause-specific survival; CI, confidence interval; HR, hazard ratio; OS, overall survival; SEER, surveillance, epidemiology, and end results*.

When adjusted by age, race, grade, histological subtypes, surgery, chemotherapy, and marital status, patients in the localized stage diagnosed in 2005**--**2009 (CSS hazard ratio \[HR\], 0.828; 95% confidence interval \[CI\], 0.694--0.988, *P* = 0.036; OS HR, 0.876; 95% CI 0.779--0.986, *P* = 0.028) and 2010--2014 (CSS HR, 0.668; 95% CI 0.538--0.831, *P* \< 0.001; OS HR, 0.783; 95% CI 0.670--0.914, *P* = 0.002) had a better CSS and OS than those diagnosed in 1990--1994. The CSS increased over time among patients in the regional stage, with patients diagnosed in 2005--2009 (HR, 0.745; 95% CI, 0.641--0.866, *P* \< 0.001) and 2010--2014 (HR, 0.802; 95% CI, 0.680--0.947, *P* = 0.009) having better OS compared to those diagnosed in 1990--1994. Patients diagnosed in later years had a higher CSS and OS in the distant stage when compared to patients diagnosed in earlier years ([Table 3](#T3){ref-type="table"}).

###### 

The 5-year cause-specific survival, overall survival, and adjusted hazard ratios for epithelial ovarian cancer patients by period of diagnosis according to SEER stage.

  **Variables**    **CSS**   **OS**                                                                                                                                                   
  ---------------- --------- ------------------------------------------ ------- -------------- --------- ------ ------------------------------------------ ------- ------------------ ---------
  **Localized**                                                                                                                                                                       
      1990--1994   91.9      0.265[^\*^](#TN1){ref-type="table-fn"}     1                                85.6   0.064[^\*^](#TN1){ref-type="table-fn"}     1                          
      1995--1999   91.9      0.210[^\#^](#TN2){ref-type="table-fn"}     0.982   0.878--1.180   0.845     87.2   0.309[^\#^](#TN2){ref-type="table-fn"}     0.978       0.877--1.090   0.685
      2000--2004   91.9      0.141[^†^](#TN3){ref-type="table-fn"}      0.910   0.771--1.075   0.269     87     0.234[^†^](#TN3){ref-type="table-fn"}      0.911   0.82101.012        0.081
      2005--2009   91.9      0.096[^‡^](#TN4){ref-type="table-fn"}      0.828   0.694--0.988   0.036     86.8   0.121[^‡^](#TN4){ref-type="table-fn"}      0.876   0.779--0.986       0.028
      2010--2014   93.1                                                 0.668   0.538--0.831   \<0.001   88.5                                              0.783   0.670--0.914       0.002
  **Regional**                                                                                                                                                                        
      1990--1994   66.4      0.022[^\*^](#TN1){ref-type="table-fn"}     1                                59.7   0.089[^\*^](#TN1){ref-type="table-fn"}     1                          
      1995--1999   72.5      0.298[^\#^](#TN2){ref-type="table-fn"}     0.806   0.659--0.985   0.035     65.0   0.430[^\#^](#TN2){ref-type="table-fn"}     0.870   0.739--1.023       0.093
      2000--2004   73.8      0.246[^†^](#TN3){ref-type="table-fn"}      0.794   0.669--0.943   0.009     67.1   0.412[^†^](#TN3){ref-type="table-fn"}      0.874   0.756--1.009       0.067
      2005--2009   75.2      0.104[^‡^](#TN4){ref-type="table-fn"}      0.670   0.562--0.800   \<0.001   69.2   0.195[^‡^](#TN4){ref-type="table-fn"}      0.745   0.641--0.866       \<0.001
      2010--2014   72.9                                                 0.756   0.625--0.916   0.004     66.9                                              0.802   0.680--0.947       0.009
  **Distant**                                                                                                                                                                         
      1990--1994   31.4      \<0.001[^\*^](#TN1){ref-type="table-fn"}   1                                26.7   \<0.001[^\*^](#TN1){ref-type="table-fn"}   1                          
      1995--1999   35.4      \<0.001[^\#^](#TN2){ref-type="table-fn"}   0.915   0.873--0.958   \<0.001   31.1   \<0.001[^\#^](#TN2){ref-type="table-fn"}   0.906   0.868--0.946       \<0.001
      2000--2004   36.9      \<0.001[^†^](#TN3){ref-type="table-fn"}    0.858   0.824--0.894   \<0.001   32.1   \<0.001[^†^](#TN3){ref-type="table-fn"}    0.865   0.833--0.898       \<0.001
      2005--2009   39.7      \<0.001[^‡^](#TN4){ref-type="table-fn"}    0.773   0.742--0.807   \<0.001   34.4   \<0.001[^‡^](#TN4){ref-type="table-fn"}    0.791   0.761--0.822       \<0.001
      2010--2014   42.7                                                 0.661   0.630--0.692   \<0.001   37.4                                              0.679   0.650--0.709       \<0.001

*CSS, cause-specific survival; CI, confidence interval; HR, hazard ratio; OS, overall survival*.

*Indicates Kaplan--Meier analyses of 5-year survival and comparisons among the five time periods using the log-rank test*.

*Indicates Kaplan--Meier analyses of 5-year survival and comparisons using the log-rank test among the last four periods (1995--1999, 2000--2004, 2005--2009, and 2010--2014)*.

*Indicates the Kaplan--Meier analyses of 5-year survival and comparisons using log-rank test among three periods (2000--2004, 2005--2009, and 2010--2014)*.

*Indicates the Kaplan--Meier analyses of 5-year survival and comparisons using the log-rank test on the last two periods (2005--2009 and 2010--2014)*.

The 5-year CSS and OS by period of diagnosis according to SEER stage are presented in [Table 3](#T3){ref-type="table"}. The period of diagnosis had no effect on the CSS and OS of patients in the localized stage ([Figures 3A,D](#F3){ref-type="fig"}). The CSS significantly improved in the regional state after 1995--2014 compared to 1990--1994, while it did not differ significantly from 1995 to 2014. The OS in the regional stage during the study period was not significantly different ([Figures 3B,E](#F3){ref-type="fig"}). However, the CSS and OS gradually increased from 1990 to 2014 in the distant stage ([Figures 3C,F](#F3){ref-type="fig"}).

![Trends in cause-specific survival (CSS) and overall survival (OS) in the localized (CSS, **A**; OS, **D**), regional (CSS, **B**; OS, **E**), and distant stages (CSS, **C**; OS, **F**) over time.](fonc-09-00639-g0003){#F3}

Discussion {#s4}
==========

The purpose of the present study was to assess trends in survival outcomes among EOC patients between 1990 and 2014. We found a 9.6% improvement in the 5-year CSS and a 10.9% improvement in the 5-year OS between 1990 and 2010, and survival showed the greatest increase among patients in the distant stage. The incidence of EOC has gradually decreased in recent decades ([@B2]). However, the absolute number of EOC cases in our study increased and was relatively stable after 2000, which may be related to changes in the histological diagnostic patterns of EOC ([@B19]). The increase in the number of cases classified as EOC may be due to better coding and recording of ovarian cancer morphology by cancer registries ([@B20]). We found approximately 25% of patients were diagnosed in the localized stage, and this proportion did not change over time, which may be related to the lack of reliable and effective screening methods to diagnosis early-stage EOC ([@B3]--[@B6]). Therefore, although the incidence of EOC is declining, there is a need to explore effective screening methods, including mathematical modeling, cancer-specific biomarkers, and real-time imaging to detect it earlier ([@B21]).

There were also several SEER studies attempted to answer similar questions, but the results were inconsistent ([@B7], [@B12], [@B14], [@B16]). A SEER study included patients from 1973 to 1997, and the results showed improved outcomes in localized, regional, and distant stage EOC over time ([@B7]). Two SEER studies included patients in later years (1988--2011 and 1992--2013) showed comparable outcomes during the periods of diagnosis ([@B12], [@B16]). However, a study only included patients with stage I-II disease ([@B12]), and another study only included Hispanic women ([@B16]), which could not represent the general population. A recent SEER study included patients from 2002 to 2011, and the results showed improved outcomes in patients with stage IV EOC, but not in patients with stage I--III disease ([@B14]). However, the information regarding sample of patients, surgery and chemotherapy were not included in this study. Although studies from Canadian and France population showed an improved outcome over time. A large cohort from Netherlands Cancer Registry indicated that long-term outcome has not improved of EOC in the last 25 years ([@B13]). As listed in [Table 4](#T4){ref-type="table"}, there were significantly differences in the inclusion criteria and patterns of treatment in the above-mentioned studies, which may be contributed to the inconsistent results. In addition, the diagnostic techniques, postoperative care, and palliative care may also have different effects on the survival outcome for patients.

###### 

The similarities and differences in present study and previous studies.

  **References**                   **Period of diagnosis**   **Population**                **No. of patients**   **Stage and histology**                               **Surgery**                                  **Chemotherapy**                             **Survival trends by period of diagnosis**
  -------------------------------- ------------------------- ----------------------------- --------------------- ----------------------------------------------------- -------------------------------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Barnholtz-Sloan et al. ([@B7])   1973--1997                SEER database                 32,845                Localized, regional, distant, and unknown stage EOC   79.0%                                        NA                                           Localized stage: 5-year OS 84, 88, and 92% in patients diagnosed in 1973--1979, 1980--1989, and 1990--1997, respectively. Regional stage: 5-year OS 49, 65, and 77% in patients diagnosed in 1973--1979, 1980--1989, and 1990--1997, respectively. Distant stage: 5-year OS 17, 22, and 27% in patients diagnosed in 1973--1979, 1980--1989, and 1990--1997, respectively.
  Chan et al. ([@B12])             1988--2001                SEER database                 8,372                 Stage I--II EOC                                       94.9%                                        NA                                           Comparable disease-specific survival by 1988--1992, 1993--1997, and 1998--2001 (*P* = 0.076).
  Tan et al. ([@B15])              1979--2001                New York State                NA                    NA                                                    NA                                           NA                                           Ovarian cancer death rates relatively constant over time.
  Akhtar-Danesh et al. ([@B10])    1992--2005                Canadian population           7,771                 EOC                                                   NA                                           NA                                           2- and 5-year relative survival improved over the period of 1992--2005.
  Trétarre et al. ([@B11])         1989--2010                France                        12,645                NA                                                    NA                                           NA                                           5-year net survival 36, 35, 42, and 44% in patients diagnosed in 1989--1993, 1994--1998, 1999--2004, and 2005--2010, respectively.
  Warren et al. ([@B14])           2002--2011                SEER database                 NA                    Stage I--IV EOC                                       NA                                           NA                                           There was an increase in 2-year cause-specific survival in stage IV EOC from 2002 to 2011, but 2-year cause-specific survival remained stable in patients with stage I--III diseases.
  Timmermans et al. ([@B13])       1989--2014                Netherlands Cancer Registry   32,540                Stage I--IV EOC                                       98.2% (early stage) 71.7% (advanced stage)   38.8% (early stage) 79.3% (advanced stage)   5-year OS 31.1, 31.7, 35.1, 34.6, and 33.7% in patients diagnosed in 1989--1993, 1994--1998, 1999--2003, 2004--2008, and 2009--2014, respectively.
  Chen et al. ([@B16])             1992--2013                SEER Hispanic women           7,780                 Localized, regional, distant, and unknown stage EOC   78.3%                                        NA                                           No significantly difference in all-cause and ovarian cancer-specific survival in patients diagnosed in 1992--1999, 2000--2006, and 2007--2013.
  Present studyNA                  1990--2014                SEER database                 59,763                Localized, regional, distant, and unknown stage EOC   93.0%                                        70.0%                                        Survival of women with EOC has improved over time.

*EOC, epithelial ovarian cancer; NA, not available; SEER, Surveillance, Epidemiology, and end results; OS, overall survival*.

Surgery remains the standard treatment for localized stage EOC. Our multivariate analysis found survival outcomes were better in 2005--2014 compared to 1990--1994. However, a slight improvement was found in CSS and OS; the 5-year CSS was 91.9% in 1990--1994 and in 2005--2009, and only a 1.2% absolute increase in OS was found between 1990--1994 and 2005--2009. A SEER study of patients with stages I-II EOC between 1988 and 2001 found the year of diagnosis was associated with better disease-specific survival in patients who received surgery that excluded lymphadenectomy, but it was not associated with better disease-specific survival in patients who received surgery that included lymphadenectomy ([@B12]). Therefore, the use of staging procedures may impact the role of period of diagnosis in EOC outcomes.

In our study, the CSS of patients diagnosed after 1995 significantly improved compared to those diagnosed in 1990--1994. This improvement might be related to the introduction of taxanes to clinical practice in EOC ([@B22]). Moreover, the proportion of optimal debulking surgeries for residual tumors ≤1 cm has increased in the past two decades, which may also account for improved outcomes in the regional disease stage between 1990--1994 and 1998--2014; it did not differ significantly between 1995 and 2015 ([@B23], [@B24]).

Our findings showed that the CSS and OS of patients in the distant stage improved over time. The reasons for improved survival may involve advances in chemotherapy, the introduction of carboplatin and paclitaxel for first-line treatment, the use of backup regimens for non-responsive tumors, and progress in developing treatments, such as PAPR-1 inhibitor and PD-L1 inhibitor ([@B8], [@B25]--[@B29]). In addition, there is also evidence of more accurate surgical staging procedures, more extensive tumor debulking surgery, and more accurate patient selection for secondary cytoreduction. Moreover, it is also possible the dissemination of evidence-based practices has had an impact on improving survival outcomes ([@B8]). Finally, significant improvements in survival outcomes may reflect the impact of new government-administrative strategies, such as having oncology multidisciplinary teams provide optimal treatment and care. Although gynecologic-oncologist consultations have increased in ovarian cancer over time, \<40% of patients who saw a gynecologic oncologist received guidelines pertaining to surgery and chemotherapy ([@B14]). A recent review of outcomes of the management of ovarian cancer found gynecologic oncologists in specialized hospitals consistently performed staging and debulking surgery better ([@B30]). Therefore, collaboration among patients, gynecologic oncologists, and institutions is crucial.

This study has many strengths. The primary strength of this study is that we used high quality, nationwide, population-based data to gain greater insight into the survival patterns of EOC patients over a long period of time. In addition, a large sample of EOC patients was included, thus providing sufficient power to detect the smallest differences in relative survival for EOC patients.

This study also has several limitations. First, the major limitation of this study was the bias of observational studies and the unavailability of several variables including performance status, comorbidities, smoking status, and obesity, which may be the possible confounders for the modeling of outcome for EOC. In addition, the completeness of chemotherapy and surgery were also not recorded in the SEER database, which might have influenced the results. Second, schedules, agents, and the number of courses of chemotherapy, target therapy, interval debulking surgery, and the extent of residual tumors after cytoreductive surgery (available data since 2010) were not recorded in the SEER database. Third, the SEER program does not include treatment data beyond 4 months after diagnosis, and the treatment strategy after disease recurrence are also not recorded. Moreover, a high rate of under-reporting chemotherapy has been found in the SEER database ([@B31]). Finally, the median follow-up in patients diagnosed after 2010 was significantly shorted compared to patients who diagnosed before 2010. However, approximately two-thirds of patients have been diagnosed as distant stage, which was associated with poor prognosis. Therefore, although the follow-up time of our study needs to be further extended to confirm the results, we believe that our study is still representative to reflect survival trend of EOC over time.

Conclusion {#s5}
==========

In conclusion, our results indicate the survival of women with EOC has improved over time. This study indicates that advances in the management of patients with EOC have improved survival, but net survival remains generally poor in distant-stage EOC. There is a need to explore additional treatment strategies to improve the survival of patients with EOC.
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